Expert Review of Anticancer Therapy

Expert Review of Anticancer Therapy is a peer-reviewed journal published by Taylor & Francis, established in 2001, covering the major issues in clinical oncology, with a 2025 impact factor of 3.0（Expert Review of Anticancer Therapy）是由（Taylor & Francis）出版的同行评审期刊，2001 年创办，涵盖临床肿瘤学的重大问题，2025 年影响因子为 3.0。

Scope

• Focuses on anticancer agents and novel therapies in development聚焦抗肿瘤药物与处于研发阶段的新型疗法。
• Covers cancer management and treatment guidelines涵盖肿瘤管理与治疗指南。
• Addresses biomarkers and diagnostics关注生物标志物与诊断。
• Includes clinical trials and their clinical implications包括临床试验及其临床意义。
• Welcomes clinically focused original research, reviews, editorials and drug profile articles, but not case reports, case series or pre-clinical work欢迎以临床为重点的原创研究、综述、社论与药物简介，但不接受病例报告、病例系列或临床前研究。

History

• Established in 2001 as part of the Expert Review series该刊 2001 年创办，属 Expert Review 系列期刊。
• It was published under the Informa healthcare imprint and is now part of Taylor & Francis该刊最初由（Informa healthcare）出版，现属（Taylor & Francis）。
• It appears twelve times a year and is MEDLINE-indexed该刊每年出版十二期，并被（MEDLINE）收录。
• It had a 2025 impact factor of 3.0该刊 2025 年影响因子为 3.0。

Editors

• The editor-in-chief is Gertjan JL Kaspers of Amsterdam UMC, Emma Children's Hospital and the Princess Maxima Center for pediatric oncology in the Netherlands现任主编为荷兰（Amsterdam UMC / Emma Children's Hospital）与（Princess Maxima Center）的 Gertjan JL Kaspers。
• The editorial board is international, with members from the USA, Italy, France, Japan, Australia and beyond编委会为国际化团队，成员来自美国、意大利、法国、日本、澳大利亚等地。
• After editorial assessment, papers are double-anonymous peer reviewed by independent referees论文经编辑初评后，由独立评审人进行双向匿名评审。
• A commissioning editor at Taylor & Francis handles pre-submission enquiries and article commissioning（Taylor & Francis）的组稿编辑负责投稿前咨询与稿件约请。